ibutamoren
Ibutamoren is a potent, long-acting, orally-active, selective, and non-peptide agonist of the ghrelin receptor and a growth hormone secretagogue, mimicking the growth hormone (GH)-stimulating action of the endogenous hormone ghrelin. It has been shown to increase the secretion of several hormones including GH and insulin-like growth factor 1 (IGF-1) and produces sustained increases in the plasma levels of these hormones while also raising cortisol levels. — Wikipedia
Clinical trial activity
6 trials · 5 clinical orgs · 0 marketing orgs
Earliest trial started Jul 1, 1998 (NCT00474279)
Timeline
Indications
Mechanism of action
- Ghrelin receptorAGONIST
GHSR agonist
It mimics the endogenous growth hormone ghrelin increasing the plasma levels of several hormones including growth hormone and insulin-like growth factor 1
Chemistry & pharmacology
SMILES
CC(C)(N)C(=O)N[C@H](COCc1ccccc1)C(=O)N1CCC2(CC1)CN(S(C)(=O)=O)c1ccccc12- Mol. weight
- 528.68 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL13817 ↗
- WikipediaIbutamoren ↗
- ChEMBLCHEMBL2105872 ↗
Also known as
- ibutamoren
- ibutamoren
- ibutamoren mesylate
- ibutamoren mesylate
- ibutamoren mesylate
- ibutamoren mesylate
- l 163191
- l 163,191
- l-163191
- l-163,191
- mk0677
- mk 0677
- mk-0677
- mk-0677
- mk-0677
- mk-0677
- mk-677
- mk-677
- mk-677
- mk-677
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01343641 | Phase 2 | Mar 1, 2009 | Merck, National Institutes of Health (NIH), University of Virginia |
| NCT00395291 | N/A | Aug 1, 2006 | Merck, National Institutes of Health (NIH), University of Virginia |
| NCT00128115 | Phase 2 | Sep 1, 2005 | Merck |
| NCT00116129 | Phase 2 | Jul 1, 2005 | Merck, Oregon Health and Science University, University of Rochester |
| NCT00074529 | Phase 2 | Oct 1, 2003 | Merck |
| NCT00474279 | Phase 1/Phase 2 (Phase 2) | Jul 1, 1998 | University of Virginia |
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck | For profit | 5 | 2 | 2 | 2003 |
| University of Virginia | Academic/Hospital | 3 | 3 | 2 | 1998 |
| National Institutes of Health (NIH) | Government | 2 | 0 | 2 | 2006 |
| Oregon Health and Science University | Academic/Hospital | 1 | 0 | 1 | 2005 |
| University of Rochester | Academic/Hospital | 1 | 1 | 1 | 2005 |